Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
The FDA and MRA are leveraging their combined strengths to host a public workshop on neoadjuvant therapy in melanoma.
Can new therapies benefit patients with early stage melanoma, where spread of disease has yet to be observed?
Between 1970 and 2009, melanoma rates increased nearly 10-fold among women under 40.
“There were so many things that were outside of my control, so I decided to focus on the things that I could do something about.”
NKTR-214 plus Opdivo has been granted an FDA breakthrough therapy designation for advanced melanoma.
Some of the most common and deadly cancers receive little attention and resources.
An interview with Michael Kaplan, president and CEO of the Melanoma Research Alliance, about curing the deadliest skin cancer
The Cytophone device was able to detect a single cancer cell in a liter of blood.
For patients, the decision to move forward with adjuvant therapy isn’t as cut and dry as it may seem.
New research asks if an alternative dosing schedule can produce the same effects with fewer side effects.
Treatment involves selecting, multiplying and reinfusing cancer-fighting immune cells.
Melanoma researchers have several experimental animal models from which to choose, each with its own advantages and disadvantages.
The panel and the audience candidly discussed lifelong prevention concerns, fear of recurrence, feelings of isolation and survivor’s guilt.
Together, these trials indicate that triple combos show promise and while there are significant toxicities, they are mostly manageable.
The Melanoma Research Foundation (MRF) invites you to join us for 2019 Miles for Melanoma SF 5k Run/Walk-11/17/19 at Golden Gate Park!
The Melanoma Research Foundation (MRF) invites you to join us for 2019 Miles for Melanoma LA 5k Run/Walk-November 16, 2019 at Griffith Park!
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.